WoundReference improves clinical decisions
 Choose the role that best describes you
Pourmoussa A, Gardner DJ, Johnson MB, Wong AK, et al.
Annals of translational medicine. Date of publication 2016 Dec 1;volume 4(23):457.
1. Ann Transl Med. 2016 Dec;4(23):457. doi: 10.21037/atm.2016.12.44. An update and review of cell-based wound dressings and their integration into clinical practice. Pourmoussa A(1), Gardner DJ(1), Johnson MB(1), Wong AK(1). Author information: (1)Division of Plastic and Reconstructive Surgery, Keck School of Medicine of USC, Los Angeles, CA 90033, USA. Chronic wounds affect over 4 million individuals and pose a significant burden to the US healthcare system. Diabetes, venous stasis, radiation or paralysis are common risk factors for chronic wounds. Unfortunately, the current standard of care (SOC) has a high relapse rate and these wounds continue to adversely affect patients' quality of life. Fortunately, advances in tissue engineering have allowed for the development of cell-based wound dressings that promote wound healing by improving cell migration and differentiation. As the available options continue to increase in quantity and quality, physicians should have a user-friendly guide to reference when deciding which dressing to use. The objective of this review is to identify the currently available biologic dressings, describe their indications, and provide a framework for integration into clinical practice. This review included 53 studies consisting of prospective and retrospective cohorts as well as several randomized control trials. Three general categories of cell-based biologic dressings were identified and nine brands were included. Cell-based biologic dressings have shown efficacy in a broad range of scenarios, and studies examining their efficacy have improved our understanding of the pathophysiology of chronic wounds. Amniotic and placental membranes have the widest scope and can be used to treat all subtypes of chronic wounds. Human skin allografts and bioengineered skin substitutes can be used for chronic ulcers but generally require a vascularized wound bed. Autologous platelet rich plasma (PRP) has shown promise in venous stasis ulcers and decubitus ulcers that have failed conventional treatment. Overall, more research is necessary to determine if these novel therapeutic options will change the current SOC, but current studies demonstrate encouraging results in the treatment of chronic wounds. DOI: 10.21037/atm.2016.12.44 PMCID: PMC5220025 PMID: 28090513 Conflict of interest statement: The authors have no conflicts of interest to declare.
Appears in following Topics:
Radiation-Induced Cutaneous Damage - Treatment, Prevention, Patient Education
Diabetic Foot Ulcer - Treatment
Cellular and/or Tissue Based Products